Cargando…
Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin
Anthracyclines are anti-neoplastic drugs presenting cardiotoxicity as a side effect. Cardiac troponins (cTn) and echocardiography are currently used to assess cardiac damage and dysfunction, but early biomarkers identifying patients in need of preventive treatments remain a partially met need. Circu...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290665/ https://www.ncbi.nlm.nih.gov/pubmed/32403263 http://dx.doi.org/10.3390/jcm9051418 |
_version_ | 1783545730877620224 |
---|---|
author | Gioffré, Sonia Chiesa, Mattia Cardinale, Daniela Maria Ricci, Veronica Vavassori, Chiara Cipolla, Carlo Maria Masson, Serge Sandri, Maria Teresa Salvatici, Michela Ciceri, Fabio Latini, Roberto Staszewsky, Lidia Irene Pompilio, Giulio Colombo, Gualtiero I. D’Alessandra, Yuri |
author_facet | Gioffré, Sonia Chiesa, Mattia Cardinale, Daniela Maria Ricci, Veronica Vavassori, Chiara Cipolla, Carlo Maria Masson, Serge Sandri, Maria Teresa Salvatici, Michela Ciceri, Fabio Latini, Roberto Staszewsky, Lidia Irene Pompilio, Giulio Colombo, Gualtiero I. D’Alessandra, Yuri |
author_sort | Gioffré, Sonia |
collection | PubMed |
description | Anthracyclines are anti-neoplastic drugs presenting cardiotoxicity as a side effect. Cardiac troponins (cTn) and echocardiography are currently used to assess cardiac damage and dysfunction, but early biomarkers identifying patients in need of preventive treatments remain a partially met need. Circulating microRNAs (miRNAs) represent good candidates, so we investigated their possible roles as predictors of troponin elevation upon anthracycline treatment. Eighty-eight female breast cancer patients administered with doxorubicin (DOX) or epirubicin (EPI) were divided into four groups basing on drug type and cTn positive (cTn+) or negative (cTn−) levels: DOX cTn−, DOX cTn+, EPI cTn− and EPI cTn+. Blood was collected at baseline, during treatment, and at follow-up. We identified plasma miRNAs of interest by OpenArray screening and single assay validation. Our results showed miR-122-5p, miR-499a-5p and miR-885-5p dysregulation in DOX patients at T0, identifying a signature separating, with good accuracy, DOX cTn− from DOX cTn+. No miRNAs showed differential expression in EPI subjects. Conversely, an anthracycline-mediated modulation (regardless of cTn) was observed for miR-34a-5p, -122-5p and -885-5p. Our study indicates specific circulating miRNAs as possible prediction markers for cardiac troponin perturbation upon anthracycline treatment. Indeed, our findings hint at the possible future use of plasma miRNAs to predict the cardiac responsiveness of patients to different anticancer agents. |
format | Online Article Text |
id | pubmed-7290665 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72906652020-06-17 Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin Gioffré, Sonia Chiesa, Mattia Cardinale, Daniela Maria Ricci, Veronica Vavassori, Chiara Cipolla, Carlo Maria Masson, Serge Sandri, Maria Teresa Salvatici, Michela Ciceri, Fabio Latini, Roberto Staszewsky, Lidia Irene Pompilio, Giulio Colombo, Gualtiero I. D’Alessandra, Yuri J Clin Med Article Anthracyclines are anti-neoplastic drugs presenting cardiotoxicity as a side effect. Cardiac troponins (cTn) and echocardiography are currently used to assess cardiac damage and dysfunction, but early biomarkers identifying patients in need of preventive treatments remain a partially met need. Circulating microRNAs (miRNAs) represent good candidates, so we investigated their possible roles as predictors of troponin elevation upon anthracycline treatment. Eighty-eight female breast cancer patients administered with doxorubicin (DOX) or epirubicin (EPI) were divided into four groups basing on drug type and cTn positive (cTn+) or negative (cTn−) levels: DOX cTn−, DOX cTn+, EPI cTn− and EPI cTn+. Blood was collected at baseline, during treatment, and at follow-up. We identified plasma miRNAs of interest by OpenArray screening and single assay validation. Our results showed miR-122-5p, miR-499a-5p and miR-885-5p dysregulation in DOX patients at T0, identifying a signature separating, with good accuracy, DOX cTn− from DOX cTn+. No miRNAs showed differential expression in EPI subjects. Conversely, an anthracycline-mediated modulation (regardless of cTn) was observed for miR-34a-5p, -122-5p and -885-5p. Our study indicates specific circulating miRNAs as possible prediction markers for cardiac troponin perturbation upon anthracycline treatment. Indeed, our findings hint at the possible future use of plasma miRNAs to predict the cardiac responsiveness of patients to different anticancer agents. MDPI 2020-05-11 /pmc/articles/PMC7290665/ /pubmed/32403263 http://dx.doi.org/10.3390/jcm9051418 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gioffré, Sonia Chiesa, Mattia Cardinale, Daniela Maria Ricci, Veronica Vavassori, Chiara Cipolla, Carlo Maria Masson, Serge Sandri, Maria Teresa Salvatici, Michela Ciceri, Fabio Latini, Roberto Staszewsky, Lidia Irene Pompilio, Giulio Colombo, Gualtiero I. D’Alessandra, Yuri Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin |
title | Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin |
title_full | Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin |
title_fullStr | Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin |
title_full_unstemmed | Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin |
title_short | Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin |
title_sort | circulating micrornas as potential predictors of anthracycline-induced troponin elevation in breast cancer patients: diverging effects of doxorubicin and epirubicin |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290665/ https://www.ncbi.nlm.nih.gov/pubmed/32403263 http://dx.doi.org/10.3390/jcm9051418 |
work_keys_str_mv | AT gioffresonia circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin AT chiesamattia circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin AT cardinaledanielamaria circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin AT ricciveronica circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin AT vavassorichiara circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin AT cipollacarlomaria circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin AT massonserge circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin AT sandrimariateresa circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin AT salvaticimichela circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin AT cicerifabio circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin AT latiniroberto circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin AT staszewskylidiairene circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin AT pompiliogiulio circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin AT colombogualtieroi circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin AT dalessandrayuri circulatingmicrornasaspotentialpredictorsofanthracyclineinducedtroponinelevationinbreastcancerpatientsdivergingeffectsofdoxorubicinandepirubicin |